<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377700</url>
  </required_header>
  <id_info>
    <org_study_id>XEL-CR-06</org_study_id>
    <nct_id>NCT02377700</nct_id>
  </id_info>
  <brief_title>Safety and Performance of a Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis</brief_title>
  <acronym>XEL-CR-06</acronym>
  <official_title>Initial Safety and Performance of the COR-VP-001 Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeltis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Q-Med Scandinavia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeltis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Xeltis developed biodegradable patch prosthesis, the Vascular Patch Model COR-VP-001, to be&#xD;
      used as a vascular patch to augment the pulmonary trunk and pulmonary arteries. The&#xD;
      prosthesis is immediately mechanically functional, while its physiochemical characteristics&#xD;
      should enable cell infiltration and tissue formation.&#xD;
&#xD;
      The Xeltis Vascular Graft Model COR-VP-001 is specifically designed to improve surgical&#xD;
      outcomes by reducing synthetic material related complications and improving hemodynamic&#xD;
      characteristics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xeltis has developed a medical device for treating pediatric cardiovascular patients&#xD;
      requiring RVOT reconstruction. Xeltis' mission is to offer 'Solutions for a Lifetime' to&#xD;
      cardiovascular patients. Xeltis has developed a unique technology based on novel&#xD;
      biodegradable bio-materials allowing the regrowth of natural heart valves or blood vessels in&#xD;
      patients' bodies from their own cells.&#xD;
&#xD;
      The principle of Xeltis' COR technology (COR stands for Cardiovascular Organ Regeneration) is&#xD;
      to implant a biodegradable prosthesis of a blood vessels that is shaped like the part to be&#xD;
      replaced. The prosthesis is immediately mechanically functional, while its physiochemical&#xD;
      characteristics should enable cell infiltration and tissue formation. Tissue is regenerated&#xD;
      and functional by the time the polymer is biodegraded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Patch Related Serious Adverse Events.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the safety of the COR-VP-001 as defined by number of patients having patch related post-operative complications requiring surgery, intervention or leading to death up to 12 months post implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Loss of Functionality of the Patch.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the performance of the COR-VP-001 by analyzing the incidence of loss of functionality requiring intervention within up to 12 months post implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Evaluation</measure>
    <time_frame>up to 12 Months after Implant</time_frame>
    <description>Number of patients with histological evaluation of the patch material obtained during the planned reoperation within up to 12 months after implantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <arm_group>
    <arm_group_label>Xeltis Vascular Patch, Model COR-VP-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xeltis Vascular Patch, Model COR-VP-001</intervention_name>
    <description>The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis</description>
    <arm_group_label>Xeltis Vascular Patch, Model COR-VP-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient requiring a bidirectional cava-pulmonary anastomosis&#xD;
&#xD;
          2. Male or Female&#xD;
&#xD;
          3. Age: 2 months to 16 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Main Exclusion Criteria Arrhythmias as determined by ECG and/or at the investigator's&#xD;
             discretion&#xD;
&#xD;
          2. Other clinically significant malformations&#xD;
&#xD;
          3. Coagulation disorders as defined by INR outside its normal value, PTT &gt;ULN and&#xD;
             Fibrinogen &lt;LLN and/or at the investigator's discretion&#xD;
&#xD;
          4. HIV-infection&#xD;
&#xD;
          5. Syphilis (Treponema pallidum)&#xD;
&#xD;
          6. Hepatitis-B and/or -C virus infection&#xD;
&#xD;
          7. Unwillingness of Parental/legal guardian to give consent&#xD;
&#xD;
          8. Treatment with other investigational products&#xD;
&#xD;
          9. Known or suspected noncompliance, drug or alcohol abuse of the parents/legal guardian&#xD;
&#xD;
         10. Inability of the parents/legal guardian to follow the procedures of the study, e.g.&#xD;
             due to language problems&#xD;
&#xD;
         11. Participation of the patient in another study within 30 days preceding and during the&#xD;
             present study&#xD;
&#xD;
         12. Previous enrolment of the patient into the current study&#xD;
&#xD;
         13. Enrolment of the investigator's family members, employees and other dependent persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo Bockeria, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bakoulev Center for Cardiovascular Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bakoulev Center for Cardiovascular Surgery</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <results_first_submitted>September 24, 2020</results_first_submitted>
  <results_first_submitted_qc>November 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2020</results_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Xeltis Vascular Patch, Model COR-VP-001</title>
          <description>Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.&#xD;
Xeltis Vascular Patch, Model COR-VP-001: The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xeltis Vascular Patch, Model COR-VP-001</title>
          <description>Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.&#xD;
Xeltis Vascular Patch, Model COR-VP-001: The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" lower_limit="0.5" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patch Related Serious Adverse Events.</title>
        <description>Evaluation of the safety of the COR-VP-001 as defined by number of patients having patch related post-operative complications requiring surgery, intervention or leading to death up to 12 months post implantation</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xeltis Vascular Patch, Model COR-VP-001</title>
            <description>Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.&#xD;
Xeltis Vascular Patch, Model COR-VP-001: The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patch Related Serious Adverse Events.</title>
          <description>Evaluation of the safety of the COR-VP-001 as defined by number of patients having patch related post-operative complications requiring surgery, intervention or leading to death up to 12 months post implantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Loss of Functionality of the Patch.</title>
        <description>Evaluation of the performance of the COR-VP-001 by analyzing the incidence of loss of functionality requiring intervention within up to 12 months post implantation.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xeltis Vascular Patch, Model COR-VP-001</title>
            <description>Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.&#xD;
Xeltis Vascular Patch, Model COR-VP-001: The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Loss of Functionality of the Patch.</title>
          <description>Evaluation of the performance of the COR-VP-001 by analyzing the incidence of loss of functionality requiring intervention within up to 12 months post implantation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histological Evaluation</title>
        <description>Number of patients with histological evaluation of the patch material obtained during the planned reoperation within up to 12 months after implantation</description>
        <time_frame>up to 12 Months after Implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xeltis Vascular Patch, Model COR-VP-001</title>
            <description>Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.&#xD;
Xeltis Vascular Patch, Model COR-VP-001: The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Evaluation</title>
          <description>Number of patients with histological evaluation of the patch material obtained during the planned reoperation within up to 12 months after implantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Xeltis Vascular Patch, Model COR-VP-001</title>
          <description>Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.&#xD;
Xeltis Vascular Patch, Model COR-VP-001: The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Stenosis in the bi-directional cava pulmonary anastomosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sick sinus syndrome and bundle branch block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia and atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eliane Schutte, CEO</name_or_title>
      <organization>Xeltis</organization>
      <phone>+31 40 751 7614</phone>
      <email>clinical@xeltis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

